Ipsen In-Licenses Parkinson's Candidate From IRLAB

Ipsen SA IPSEY and IRLAB have signed a licensing agreement, providing Ipsen exclusive rights to mesdopetam.
Under the terms of the agreement, IRLAB will be eligible to receive up to $363 million, including an upfront cash payment of $28 million and up to $335 million in milestone payments.
IRLAB is also eligible to receive tiered low double-digit royalties on worldwide net sales of mesdopetam.
Mesdopetam (IRL790) is a dopamine D3-receptor antagonist being developed to prevent and treat levodopa-induced dyskinesias and psychosis in Parkinson’s.
Price Action: IPSEY shares traded at 25.71 during the market session on the last check Thursday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.